William T. McMillen

Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor-β Type I Receptor Kinase Domain

J. Scott Sawyer, Bryan D. Anderson, Douglas W. Beight et al. · Journal of Medicinal Chemistry · 2003 · 237 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Jonathan M. Yingling, William T. McMillen, Lei Yan et al. · Oncotarget · 2017 · 173 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +12

Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain

J. Scott Sawyer, Douglas W. Beight, Karen S. Britt et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 163 citations

Pharmacy, Medicinal Chemistry, Pharmacology +14

ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

Shripad V. Bhagwat, William T. McMillen, Shufen Cai et al. · Molecular Cancer Therapeutics · 2019 · 108 citations · Full text

Medicine, Oncology, Pharmacology +17

Kinetic Characterization of Novel Pyrazole TGF-β Receptor I Kinase Inhibitors and Their Blockade of the Epithelial−Mesenchymal Transition

Sheng-Bin Peng, Lei Yan, Xiaoling Xia et al. · Biochemistry · 2005 · 99 citations

Life Sciences, Cell Biology, Pharmacology +14